MGLUR5 POSITIVE ALLOSTERIC MODULATORS FOR USE IN THE TREATMENT PHELAN-MCDERMID SYNDROME

摘要

The invention concerns a novel therapeutic application for positive allosteric modulators of the metabotropic glutamate receptor mGluR5, notably for the therapeutic treatment of Phe- lan-McDermid syndrome caused by 22qI3 deletion. For this purpose, a preferred positive allosteric modulator is 3-cyano-N-(1,3-diphenyl-1-H-pyrazol-5-yl)benzamide, abbreviated as CDPPB.